DDInter1397 DDInter262
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cabozantinib
Paroxetine {u} (Compound) causes {v} (Side Effect) Vulvovaginal candidiasis
Vulvovaginal candidiasis {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cabozantinib
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Paroxetine {u} (Compound) causes {v} (Side Effect) Vulvovaginal candidiasis
Vulvovaginal candidiasis {u} (Side Effect) is caused by {v} (Compound) Aripiprazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Paroxetine {u} (Compound) causes {v} (Side Effect) Vulvovaginal candidiasis
Vulvovaginal candidiasis {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Paroxetine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Tamoxifen
Tamoxifen {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Paroxetine {u} (Compound) causes {v} (Side Effect) Pyuria
Pyuria {u} (Side Effect) is caused by {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Paroxetine (Compound) causes Vulvovaginal candidiasis (Side Effect) and Vulvovaginal candidiasis (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Paroxetine (Compound) causes Vulvovaginal candidiasis (Side Effect) and Vulvovaginal candidiasis (Side Effect) is caused by Aripiprazole (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Paroxetine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Paroxetine (Compound) causes Vulvovaginal candidiasis (Side Effect) and Vulvovaginal candidiasis (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may lead to a major life threatening interaction when taken with Cabozantinib
Paroxetine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Cabozantinib
Paroxetine (Compound) causes Pyuria (Side Effect) and Pyuria (Side Effect) is caused by Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Flurbiprofen may lead to a major life threatening interaction when taken with Cabozantinib
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Cabozantinib